NCT00653770View on ClinicalTrials.gov

A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Tuberculosis
Interventions
BIOLOGICAL

FP85A

Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)

BIOLOGICAL

MVA85A

Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)

Trial Locations (1)

OX3 7LJ

CCVTM, University of Oxford, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT00653770 - A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A | Biotech Hunter | Biotech Hunter